SCHEMBL31292288

SCHEMBL31292288

CCOC(=O)C(C)(C)c1ccc(SCc2ccccc2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP8 P22894 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.38
▸ RECQL P46063 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CNR2 P34972 5/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ PIN1 Q13526 1/20 0.36
▸ F2 P00734 2/20 0.36
▸ F10 P00742 2/20 0.36
▸ PLG P00747 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902227 0.78 SMN1; SMN2 (0.49) ALDH1A1KMT2ANPC1TSHRNFKB1
SCHEMBL31190873 0.77 POLB (0.41) ALDH1A1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL23876178 0.74 PTPN1 (0.45) ALDH1A1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL30192734 0.73 CNR2 (0.45) ALDH1A1CNR2NPC1TSHRRAB9A
SCHEMBL14035562 0.73 CNR2 (0.45) ALDH1A1CNR2NPC1TSHRRAB9A
SCHEMBL31292359 0.73 CNR2 (0.45) MMP8ALDH1A1CNR2TSHRF2
SCHEMBL3800355 0.72 CNR2 (0.44) MMP8CNR2NPC1MAOB
SCHEMBL395978 0.72 PIN1 (0.54) MMP8ALDH1A1RECQLKMT2ACNR2
Benzene SCHEMBL28258998 0.72 PIN1 (0.54) MMP8ALDH1A1RECQLKMT2ACNR2
SCHEMBL23876181 0.71 PPARG (0.44) ALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 — — US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 — — US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 — — US disclosed
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MMP8 412/4885ALDH1A1 4061/4885RECQL 3603/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 MMP8 409/4885ALDH1A1 4050/4885RECQL 3621/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MMP8 412/4885ALDH1A1 4061/4885RECQL 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback